Tamoxifen (Standard)

Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A) . This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[1][2][3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[5]. Tamoxifen activates autophagy and induces apoptosis[4]. Tamoxifen also can induce gene knockout of CreER (T2) transgenic mouse[6].

Product Specifications

CAS Number

[10540-29-1]

Product Name Alternative

ICI 47699 (Standard) ; (Z) -Tamoxifen (Standard) ; trans-Tamoxifen (Standard)

UNSPSC

12352005

Hazard Statement

H302, H350, H360, H410

Target

Apoptosis; Autophagy; Estrogen Receptor/ERR; HSP; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/tamoxifen-standard.html

Purity

99.94

Smiles

CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3

Molecular Formula

C26H29NO

Molecular Weight

371.51

Precautions

H302, H350, H360, H410

References & Citations

[1]Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339 (22) :1609-18.|[2]Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18 (6A) :4383-6.|[3]Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177 (5) :1280-1292.e20.|[4]Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5 (4) :e9934.|[5]Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279 (32) :34048-61.|[6]Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63.|[7]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.|[8]El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38 (5) :563-70. |[9]El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38 (3) : 300-306.|[10]Buchanan C M, et al. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen–hydroxybutenyl-β-cyclodextrin formulations[J]. Journal of pharmaceutical sciences, 2007, 96 (3) : 644-660.